Start › Nowotwór przerzutowy › Waszyngton › Washington
Badania kliniczne dla Nowotwór przerzutowy w mieście Washington, DC
43 badań dla Nowotwór przerzutowy szuka uczestników w ośrodkach w mieście Washington i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RekrutacjaFaza 2
- Walter Reed National Military Medical Center, Bethesda · 7 mi dalej
- National Institutes of Health Clinical Center, Bethesda · 7 mi dalej
The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
RekrutacjaFaza 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi dalej
A Study of ASP3082 in Adults With Advanced Solid Tumors
RekrutacjaFaza 1
- Georgetown University Hospital, Washington D.C.
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
RekrutacjaFaza 2/3
- Georgetown University, Washington D.C.
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
RekrutacjaFaza 1
- Johns Hopkins Sibley Memorial Hospital, Washington D.C.
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
RekrutacjaFaza 2
- The George Washington Medical facility Associates, Washington D.C.
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
RekrutacjaFaza 2/3
- Georgetown University Medical Center - Department of Pharmacy, Oncology Pharmacy, Washington D.C.
- Georgetown University Medical Center, Washington D.C.
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RekrutacjaFaza 3
- Maryland Oncology Hematology, P.A., Silver Spring · 7 mi dalej
- Maryland Oncology Hematology, P.A., Bethesda · 7 mi dalej
- Maryland Oncology Hematology, P.A., Largo · 11 mi dalej
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
RekrutacjaFaza 1/2
- Georgetown University Medical Center, Washington D.C.
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RekrutacjaFaza 3
- MedStar Washington Hospital Center, Washington D.C.
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RekrutacjaFaza 3
- MedStar Washington Hospital Center, Washington D.C.
- American Oncology Partners, PA, Bethesda · 7 mi dalej
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
RekrutacjaFaza 1/2
- MedStar Georgetown Cancer Institute at MedStar Washington Hospital Center ( Site 0026), Washington D.C.
Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers
RekrutacjaFaza 1
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda · 7 mi dalej
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
RekrutacjaFaza 1/2
- Clinical Study Site, Washington D.C.
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
RekrutacjaFaza 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi dalej
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
RekrutacjaFaza 2
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda · 7 mi dalej
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RekrutacjaFaza 3
- Sibley Memorial Hospital, Washington D.C.
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
RekrutacjaFaza 1/2
- Avenzo Therapeutics Recruiting Site, Washington D.C.
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
RekrutacjaFaza 3
- The Center for Cancer and Blood Disorders a division of American Oncology Partners, P.A., Bethesda · 7 mi dalej
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
RekrutacjaFaza 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi dalej
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
RekrutacjaFaza 1
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda · 7 mi dalej
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
RekrutacjaFaza 2
- Research Site, Washington D.C.
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RekrutacjaFaza 1/2
- Johns Hopkins University, Sibley Memorial Hospital, Washington D.C.
Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers
RekrutacjaFaza 1
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda · 7 mi dalej
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
RekrutacjaFaza 1
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda · 7 mi dalej
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
RekrutacjaFaza 1/2
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda · 7 mi dalej
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RekrutacjaFaza 3
- Research Site, Washington D.C.
- Research Site, Silver Spring · 7 mi dalej
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
RekrutacjaFaza 1/2
- George Washington University, Washington D.C.
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
RekrutacjaFaza 3
- MedStar Washington Hospital Center, Washington D.C.
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RekrutacjaFaza 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi dalej
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
RekrutacjaFaza 1/2
- Georgetown University Medical Center, Washington D.C.
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
RekrutacjaFaza 3
- American Oncology Partners, P.A., Bethesda · 7 mi dalej
Studying TAK-243 in Patients With Advanced Cancer
RekrutacjaFaza 1
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda · 7 mi dalej
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
RekrutacjaFaza 2/3
- The Center for Cancer and Blood Disorders, Bethesda · 7 mi dalej
Cancer Experience Registry (CER) for Cancer Patients and Caregivers
RekrutacjaBadanie obserwacyjneZapraszamy zdrowych ochotników
- Cancer Support Community Research & Training Institute, Washington D.C.
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
RekrutacjaFaza 3
- The George Washington University, Washington D.C.
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
RekrutacjaFaza 2/3
- Washington DC VA Medical Center, Washington, DC, Washington D.C.
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
RekrutacjaFaza 2/3
- Georgetown University Medical Center, Washington D.C.
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RekrutacjaFaza 1
- National Cancer Institute, Bethesda · 7 mi dalej
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
RekrutacjaFaza 1
- Georgetown University Medical Center, Washington D.C.
- Sibley Memorial Hospital, Washington D.C.
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
RekrutacjaFaza 1
- American Oncology Partners of Maryland, Bethesda · 7 mi dalej
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
RekrutacjaFaza 1/2
- The George Washington University Cancer Center (site 212), Washington D.C.
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekrutacjaBadanie obserwacyjne
- Massive Bio SYNERGY-AI site, Silver Spring · 7 mi dalej
- Massive Bio SYNERGY-AI site, Bethesda · 7 mi dalej
Badania dla Nowotwór przerzutowy w innych miastach
- Houston, TX104 badań
- New York City, NY93 badań
- Nashville, TN70 badań
- Boston, MA63 badań
- Los Angeles, CA57 badań
- St. Louis, MO54 badań
- Arlington, VA53 badań
- Philadelphia, PA46 badań
- Chicago, IL45 badań
- San Antonio, TX44 badań
- Dallas, TX42 badań
- Seattle, WA39 badań
Inne badania w mieście Washington
- Nowotwory (wszystkie typy)58 badań
- Niedrobnokomórkowy rak płuca55 badań
- Rak piersi46 badań
- Rak płuc41 badań
- Rak prostaty38 badań
- Otyłość33 badań
- Rak jelita grubego i odbytnicy29 badań
- Choroby układu sercowo-naczyniowego28 badań
- Rak pęcherza moczowego26 badań
- Ostra białaczka szpikowa24 badań
- Rak jajnika23 badań
- Chłoniak23 badań
Źródło: ClinicalTrials.gov, dane pobrane 6 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.